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Open access under the ElRaltegravir is an integrase inhibitor (INI) licensed for clinical use and other INI are in advanced stage of
development. Different resistance mutations in HIV integrase from patients using these antiretroviral
drugs have been described and G148H/R/K, N155H and less frequently Y143C/H/R are considered major
resistant mutations to raltegravir. Both Stanford Database and Geno2Pheno list F121Y as conferring inter-
mediate resistance ‘‘in vitro’’ both to raltegravir and elvitegravir. We report for the ﬁrst time the ‘‘in vivo’’
selection F121Y and evolution to Y143R in a 31 years old male clade B HIV-1 infected patient failing a
raltegravir-containing salvage regimen. Plasma samples nine months prior to raltegravir (RAL-Naïve)
and at weeks 32, 40 and 88 after RAL-containing regimen were analyzed. Antiretroviral susceptibility
was evaluated at Stanford and Geno2Pheno from sequences obtained with RT-PCR. After a Viral load at
week 12 below 50 copies/mL, viremia raised at week 20 to 4.5log10. The emergence of F121Y was
observed at week 32 and 40, alongside with L74I, T97A, Q137H and V151I. At week 88 F121Y was no
longer detected, L74I and T97A were maintained and Y143R emerged. F121Y might be an alternative
pathway to Y143R. Changing of RAL-containing regimen upon the identiﬁcation of F121Y might avoid
the evolution of raltegravir resistance.
 2012 Elsevier B.V. Open access under the Elsevier OA license. Integrase inhibitors (INIs) are an important addition to the HIV
infection treatment armamentarium. Licensed in 2007, raltegravir
(RAL, Merck Laboratories) is the ﬁrst INI approved for clinical use
(FDA, 2007). Other drugs in this class, such as elvitegravir (Gilead
Sciences) and dolutegravir (GlaxoSmithKline), are in advanced stage
of development (van Lunzen et al., 2012; Molina et al., 2012). In
Brazil, raltegravir is used as part of salvage regimens of patientswith
documented resistance to multiple antiretroviral drugs (http://
www.aids.gov.br/sites/default/ﬁles/folder_consenso.pdf).
Despite its high activity when combined with optimized back-
ground therapy (OBT), different mutations confer loss of suscepti-
bility to raltegravir, as well as to other INIs (Steigbigel et al.,
2008; Shimura et al., 2008; Rowley, 2008; Malet et al., 2009; Mbisa
et al., 2011). The pathways G148H/R/K, N155H and, less frequently
Y143C/H/R, lead to an important viral resistance to raltegravir
(Cooper et al., 2008). Also, some of these mutations also confer
cross-resistance to other INIs, such as Q148H/R/K to elvitegravir
(Shimura et al., 2008; Malet et al., 2009; Mbisa et al., 2011; Blancotrovírus, Centro de Virologia,
César, 01246-902 São Paulo,
983.
edo Brígido).
sevier OA license. et al., 2011). Dolutegravir seems less susceptible to genetic
resistance (Canducci et al., 2011), but different combinations of
substitutions Q148H/K/R, G140S/A and E138 K/A may reduce its
susceptibility by 10- to 20-fold (http://hivdb.stanford.edu/pages/
drugSummaries.html). Along substitutions associated to the loss
of susceptibility to raltegravir, non polymorphic accessory muta-
tions can emerge during therapy as result of selective pressure.
Moreover, natural polymorphisms of the integrase gene, such as
V151I and I72 V, have been associated to a small decrease in sus-
ceptibility to INIs (Passaes et al., 2009; Low et al., 2009). Marinello
et al. (2008) documented the negative impact of the F121Y substi-
tution on integrase strand transfer activity, while integration pat-
terns remains unchanged. Moreover, albeit never described in
clinical isolates, HIV Stanford Resistance Database and Geno2Pheno
both list 121Y as conferring a 5–10-fold decrease in raltegravir
(Kobayashi et al., 2008; Rowley, 2008; Blanco et al., 2011) and elvi-
tegravir (Shimura et al., 2008) susceptibility, leading to an interme-
diate resistance proﬁle. Identiﬁcation of potential mutational
pathways is important to understand the evolution of resistance
patterns and the drug susceptibility in HIV-1 infection.
In the present study we report the in vivo selection of the non-
polymorphic substitution F121Y in a31 years oldmalepatient, diag-
nosed in August 1998 with HIV-1 infection, who underwent six
10 J.S. Cavalcanti Antiviral Research 95 (2012) 9–11treatment regimens (starting with HAART: zidovudine, lamivudine
and nevirapine) prior to the use of RAL-containing therapy.We eval-
uated the evolution of the viral integrase from a genotype previous
fully susceptible to integrase inhibitors to a F121Y intermediate
resistant strain, and subsequently to an Y143R fully resistant proﬁle
analyzing protease/reverse transcriptase (referred as ‘‘polymerase’’)
and integrase genotypic population sequencing from blood samples
prior to raltegravir exposure, collected in 2009 (RAL-NAÏVE), and at
weeks 32, 40 and 88 after introduction of RAL-containing regimen.
Viral RNA was extracted using the QIAamp Viral RNAMini Kit (Qia-
gen, Germany) according to manufacturer instructions. Viral load
was determined using bDNA method (Versant 3.0 Siemens, Ger-
many) and CD4 + T-cells were measured by ﬂow cytometer (FACS
Calibur, BD, USA) during regular clinical follow up at the local labo-
ratory. The study was approved by the ethical committees of the
institutions involved.
Polymerase genotyping was performed using TRUGENE HIV-1
Genotyping Assay or OpenGene DNA System (Siemens, USA) and
a one step RT-PCR using proof reading enzyme, adapted from Van
Laethem et al. 2008, followed by a nested PCR to amplify the com-
plete integrase gene. The PCR product was then submitted to direct
sequencing using BigDye v3.1 Cycle Sequencing kit (Applied Bio-
systems, USA), resolved in an ABI3130XL (Applied Biosystems,
USA). Three independent replicate integrase sequences were ob-
tained from each sample. The sequences were assembled and edi-
ted using Sequencher 4.7 (GeneCodes, USA). Sequences Accession
numbers: JQ797715 to JQ797734.
Resistance mutations and susceptibility to antiretroviral drugs
were analyzed according to Stanford Resistance Database (Supple-
mentary data 1, SD-1), Geno2pheno[resistance], IAS 2011 mutation
list (Johnson et al., 2011) and the ANRS algorithm. Sequences were
aligned with HXB2 reference sequence using BioEdit v.7.0.9. Sub-
type screening was done at NCBI Genotyping and REGA BioAfrica
websites, conﬁrmed by phylogenetic reconstruction of Neighbor
Joining and Maximum Likelihood trees using Paup⁄ 4.10b (SD-2).
Viral load, CD4, antiretroviral treatment, resistance mutations
and sampling time points are depicted in SD-3.
Polymerase genotyping (see SD-1) prior to raltegravir exposure
predicted a high-level resistance proﬁle to all NNRTI and NRTI ex-
cept for etravirine, which showed a potential low-level resistance
score according to Stanford Database (G190A). As the patient had
no prior exposure to the drug and did not use other NNRTI in the
year preceding this sampling, the drug was considered here as fully
active. The virus had high-level resistance to all PI drugs except for
darunavir/r, which exhibited an intermediate resistance proﬁle
(I47V, I50V, I84V, L89V). Therefore, the patient started raltegravir
regimens at best with one additional active drug (etravirine) and
one partially active drug, darunavir/r. This fact may have been
determinant for the virological failure within a few weeks. Samples
weeks 40 and 88 showed high resistance to etravirine (E138Q,
Y181C and G190A). Therefore, after 40 week of exposure the regi-
men contained only a partially active darunavir.
On the ﬁrst available sample obtained after raltegravir intro-
duction on the regimen (week 32) the substitution F121Y was
observed on all replicate sequences. Alongside this mutation, the
emergence of L74I, T97A, Q137H and V151I was observed, as
well as synonymous polymorphisms in codon 167. Mutations pre-
viously described with F121Y ‘‘in vitro’’, as T124A and T125 K
(Menéndez-Arias, 2010) were not found in these sequences. No
relevant change was observed from week 32 to week 40. At week
88, a reversion was observed at positions F121Y, Q137H and V151I
to the wild type amino acid, maintaining T97A and showing the
emergence of K42R, V72I, L234I, V258I and the major resistance
mutation Y143R. T97A is a polymorphic substitution, selected by
raltegravir and is related to Y143R/C (Canducci et al., 2009).
Although not directly associated to resistance, this mutation issynergic to Y143 resistant mutants, as it is capable of restoring
the replication capacity of the virus (ﬁtness), and it is expected
to emerge after the ﬁxation of 143R (Delelis et al., 2010; Reigadas
et al., 2011). The viral load documented during the presence of
F121Y and T97A is over half log below historical values. However,
it was also documented during previous regimens (SD-3) and
therefore cannot associate these mutations to a change in replica-
tive ﬁtness.
To determine the proportion of polymorphic positions in the
integrase gene and contextualize the amino acid substitutions of
the patient’s virus, all 5102 complete integrase sequences available
at LANL were downloaded. Subtype B sequences (‘‘B global’’ align-
ment, n = 2523) were selected for amino acid composition compar-
ison. As expected, the consensus of those sequences was identical
to the Consensus B available at LANL. The RAL-NAÏVE sample did
not exhibit resistance mutations to integrase inhibitors, but had
mutations both in polymorphic positions, as E11D, observed in
26.9% of the B global alignment, as well as in non polymorphic
positions, such as Q164 K, occurring in only 0.0004% of sequences.
See Supplementary data 4 for amino acid alignment of all study
time points. In addition to amino acid substitutions, silent nucleo-
tide substitutions were observed. In a total of 13 nucleotide substi-
tutions in 143-strains, ﬁve were observed only in 121-strains. This
could indicate an evolution of 143-strains from a 121-strain pre-
cursor. Analysis of the phylogenetic reconstruction shows an evo-
lutionary pattern, with the RAL-Naïve sequences situated closer
to the main subtype B branches, with raltegravir resistant strains
further away on the branch. However, the weeks 32/40 (121-
strains) and week 88 sequences (143-strains) are located at two
separate terminal branches (bootstrap 89), which may suggest an
independent evolution of both ‘‘121Y’’ and ‘‘143R’’ strains. Our data
therefore cannot determine if a 121Y variant is the origin of the
143R variants of if it evolved directly from other precursors.
In conclusion, this study documents the association of the
emergence of F121Y plus L74I, T97A, Q137H and V151I mutational
pattern to the virological failure of RAL-containing regimen, fol-
lowed by a reversion of the F121Y substitution and appearance
of Y143R after continuous exposure to the drug. Thus, these results
reinforce the role of F121Y on raltegravir resistance, and suggest
that F121Y could be an alternative resistance pathway to raltegra-
vir, less ﬁt and therefore substituted by 143R strains. F121Y and
these secondary mutations could also be an intermediate step to-
wards the emergence of Y143R. However new generation sequenc-
ing or clonal studies are necessary to clarify the mutational
pathways and phenotypic studies are necessary to elucidate the
impact of these mutations on drug susceptibility and on integrase
activity. In either way the change of RAL-containing regimen upon
the identiﬁcation of F121Y might avoid the evolution of raltegravir
resistance.
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